KRAS and neoplasm: Recent evidence suggests clinically relevant interactions between RAS mutations and immuno-oncology (IO) biomarkers.10,11 However, the extent of relationships between microsatellite instability-high (MSI-H)/mismatch repair deficient status, tumor mutational burden (TMB), programmed death ligand 1 (PD-L1), and KRAS mutations remains unclear.